All In Biotech

Drug Trial Radar · NCT00124475

Efficacy and Safety of a Retinoid for the Treatment of Severe Chronic Hand Dermatitis

Efficacy and Safety of BAL4079 in the Treatment of Severe Refractory Chronic Hand Dermatitis

Last checked: Nov 20, 2026Latest source record: May 10, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 1,035 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

1,035

Actual

Start

Dec 2004

Primary completion

Oct 2006

Study completion Sep 2007

Sponsor

Lead sponsor
Basilea PharmaceuticaIndustry
Sponsor type
Industry
First posted
Jul 28, 2005

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of the study is to determine the therapeutic effect of alitretinoin, a retinoid, on severe, therapy refractory chronic hand dermatitis.

Conditions

  • Hand Dermatoses

Interventions

  • alitretinoinDrug

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Physicians global assessment
  2. at week 12 or 24

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Thomas Ruzicka, MD

    Düsseldorf, Germany

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.